NCT06685237Recruiting
Copenhagen Heart Failure With Preserved Ejection Fraction
CoPenhagen Heart Failure With Preserved Ejection Fraction (CPH-HFpEF)
Source: ClinicalTrials.gov · Last updated 5 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, \> 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification and management. Ensuring successful treatment necessitates early identification of HFpEF. Consequently, a targeted screening strategy has been devised for the identification of HFpEF patients. Given the higher prevalence of heart failure (HF) in the elderly population, testing the screening strategy is imperative to customize it to the specific needs of vulnerable patients who may be more inclined to decline participation in the screening program.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 11 Nov 2024
- Start date
- 28 Feb 2025
- Primary completion date
- 28 Nov 2025
- Lead sponsor
- Tor Biering-Sørensen
- Diseases
- Heart failure
- NCT number
- NCT06685237
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 28 Feb 2025 to the primary completion date, 28 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior solid organ transplantation
Other illness
- Dementia
- Cancer diagnosed within the past 5 years (skin cancer not included)
- Lung disease defined as any of the following:
- World Health Organization Group 1 pulmonary hypertension
- Chronic pulmonary embolism
- Lung fibrosis
- Chronic obstructive pulmonary disease (COPD)
- Home oxygen
Age
- Age ≥ 90 years
Other
- Prevalent HF
- Nursing home
- Amyloidosis
- Hemodialysis
Who the study is looking for
- Residence in the Capital Region of Denmark
- Age ≥ 50 years
- At least two risk factors for HFpEF defined as any of the following (for age ≥ 60 years, only one):
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Atrial fibrillation
- BMI \> 25 kg/m2
- Previous heart valve surgery
- Ischemic heart disease
- Obstructive sleep apnea
- Furosemide 40 mg
Age in the registry: 50 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital Coordinator of this site? Confirm its status | Hellerup | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.